

Manuscript Number: CRYO-D-11-00101R2

Title: Cryoprotective agent toxicity interactions in human articular chondrocytes

Article Type: Research Paper

Keywords: cryopreservation; vitrification; chondrocytes; toxicity; cryoprotectant agents; interactions

Corresponding Author: Dr. Nadr M Jomha, PhD, MD, FRCS(C)

Corresponding Author's Institution: University of Alberta

First Author: Khaled A Almansoori, MBBCh

Order of Authors: Khaled A Almansoori, MBBCh; Vinay Prasad, PhD; Fraser Forbes, PhD; Garson K Law, MSc; Locksley E McGann, PhD; Janet A W Elliott, PhD; Nadr M Jomha, MD, PhD, FRCS(C)

Abstract: Background: Vitrification is a method of cryopreservation by which cells and tissues can be preserved at low temperatures using cryoprotective agents (CPAs) at high concentrations (typically $\geq 6M$) to limit the harmful effects of ice crystals that can form during cooling processes. However, at these concentrations CPAs are significantly cytotoxic and an understanding of their toxicity characteristics and interactions is important. Therefore, single-CPA and multiple-CPA solutions were evaluated for their direct and indirect toxicities on chondrocytes. Methods: Chondrocytes were isolated from human articular cartilage samples and exposed to various single-CPA and multiple-CPA solutions of five common CPAs (dimethyl sulfoxide (DMSO), ethylene glycol (EG), propylene glycol (PG), glycerol (Gy) and formamide (Fm) at both 6.0M and 8.1M concentrations at 0°C for 30 minutes. Chondrocyte survival was determined using a fluorescent cell membrane integrity assay. The data obtained was statistically analyzed and regression coefficients were used to represent the indirect toxicity effect which a specific combination of CPAs exerted on the final solution's toxicity.

Results: Multiple-CPA solutions were significantly less toxic than single-CPA solutions ($P < 0.01$). The indirect toxicity effects between CPAs were quantifiable using regression analysis. Cell survival rates of approximately 40% were obtained with the four-CPA combination solution DMSO-EG-Gy-Fm. In the multiple-CPA combinations, PG demonstrated the greatest degree of toxicity and its presence within a combination solution negated any benefits of using multiple lower concentration CPAs.

Conclusions: Multiple-CPA solutions are less cytotoxic than single-CPA solutions of the same total concentration. PG was the most toxic CPA when used in combinations. The highest chondrocyte survival rates were obtained with the 6.0M DMSO-EG-Gy-Fm combination solution.

NOTICE: this is the author's version of a work that was accepted for publication in *Cryobiology*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Cryobiology*, Volume 64, Issue 3, June 2012, Pages 185-191. <http://dx.doi.org/10.1016/j.cryobiol.2012.01.006>.

28 **Abstract**

29 **Background:** Vitrification is a method of cryopreservation by which cells and
30 tissues can be preserved at low temperatures using cryoprotective agents (CPAs) at high
31 concentrations (typically $\geq 6M$) to limit the harmful effects of ice crystals that can form
32 during cooling processes. However, at these concentrations CPAs are significantly
33 cytotoxic and an understanding of their toxicity characteristics and interactions is
34 important. Therefore, single-CPA and multiple-CPA solutions were evaluated for their
35 *direct* and *indirect* toxicities on chondrocytes. **Methods:** Chondrocytes were isolated
36 from human articular cartilage samples and exposed to various single-CPA and multiple-
37 CPA solutions of five common CPAs (dimethyl sulfoxide (DMSO), ethylene glycol
38 (EG), propylene glycol (PG), glycerol (Gy) and formamide (Fm) at both 6.0M and 8.1M
39 concentrations at 0°C for 30 minutes. Chondrocyte survival was determined using a
40 fluorescent cell membrane integrity assay. The data obtained was statistically analyzed
41 and regression coefficients were used to represent the indirect toxicity effect which a
42 specific combination of CPAs exerted on the final solution's toxicity. **Results:** Multiple-
43 CPA solutions were significantly less toxic than single-CPA solutions ($P < 0.01$). The
44 *indirect* toxicity effects between CPAs were quantifiable using regression analysis. Cell
45 survival rates of approximately 40% were obtained with the four-CPA combination
46 solution DMSO-EG-Gy-Fm. In the multiple-CPA combinations, PG demonstrated the
47 greatest degree of toxicity and its presence within a combination solution negated any
48 benefits of using multiple lower concentration CPAs. **Conclusions:** Multiple-CPA
49 solutions are less cytotoxic than single-CPA solutions of the same total concentration. PG
50 was the most toxic CPA when used in combinations. The highest chondrocyte survival
51 rates were obtained with the 6.0M DMSO-EG-Gy-Fm combination solution.

52

53 Key words: cryopreservation, vitrification, chondrocytes, toxicity, cryoprotectant agents,

54 interactions

55

56 **Introduction**

57 Osteoarthritis (OA) results in a massive socioeconomic burden with significant
58 individual implications. Arthritis is the leading cause of work disability in Canada, with a
59 yearly economic cost of approximately \$4.4 billion in Canada[1; 2] and \$40 billion in the
60 USA[3]. Thus, prevention and treatment of OA are of paramount importance to society.
61 Although several methods are available to treat small articular cartilage (AC) injuries,
62 treatment options for larger defects have been challenging. Cartilage transplantation is a
63 potential treatment option for large cartilage defects, especially when considering the low
64 immunogenicity and avascularity of the tissue[4]. Hypothermic storage at 4°C has had
65 some success but the storage period is limited to 28-42 days because cell deterioration
66 and death begins after 7-14 days in this condition[5; 6] making it difficult to establish a
67 sufficient inventory of osteochondral tissue. Thus, before osteochondral transplantation
68 becomes widely available, an effective method of storage and preservation is necessary to
69 maintain the cartilage tissue's integrity and cellular viability. Cryopreservation offers a
70 solution to this problem by which sub-zero temperatures are used to arrest the
71 biochemical reactions responsible for the deterioration of stored cells and tissues.

72 Two common methods of cryopreservation are controlled freezing and
73 vitrification, and both have been successfully applied to single cell systems including
74 semen, stem cells, and oocytes[7; 8; 9]. However, successful long term results have been
75 limited when these techniques have been applied to more complex tissue like AC[10; 11;
76 12]. The primary obstacle of controlled freezing is the formation of ice crystals during the
77 cooling process which results in molecular, mechanical, and osmotic cellular and tissue
78 injuries[13; 14; 15]. Vitrification appears to exhibit greater survival rates for both

79 gonocytes[16; 17] and chondrocytes[18]. This process involves the use of cryoprotective
80 agents (CPAs) at high concentrations (typically $\geq 6M$ for human chondrocytes) with a
81 rapid cooling rate that limits the formation of ice crystals. Unfortunately, at the high
82 concentrations required to achieve vitrification, the CPAs are cytotoxic and so the
83 benefits of employing CPAs becomes undermined by their own toxicity[15; 19; 20; 21;
84 22].

85 In general, CPAs are categorized as *permeating* (eg. glycerol, ethylene glycol) or
86 *non-permeating* (eg. sucrose, trehalose) based on their ability to penetrate the cell
87 membrane layer. The mechanisms by which CPAs cross the cell membrane have not been
88 completely established, but studies have shown that factors which include temperature,
89 exposure time, solution agitation, and concentration can all affect their penetration into
90 cells[23; 24; 25; 26; 27; 28; 29; 30; 31]. Membrane permeation enhances a CPAs ability
91 to achieve successful cryopreservation but also makes them considerably more toxic
92 relative to non-permeating CPAs[32]. The extensive experience and relative success with
93 permeating CPAs were the reasons that this study focused exclusively on commonly used
94 permeating CPAs.

95 Different CPAs exhibit various degrees and mechanisms of toxicity. Dimethyl
96 sulfoxide (DMSO) has been investigated most thoroughly in different cell types and is
97 shown to block Na^+ and Ca^{2+} ion channels within cell membranes[33], alter cell
98 membrane permeability[34], alter mitochondrial membrane potential[35; 36], induce
99 cellular apoptosis[37], and inhibit telomerase activity[38]. Ethylene glycol (EG) has been
100 shown to induce changes to the cell's metabolism by altering NAD/NADH ratios
101 required for ATP production[39]; glycerol (Gy) is found to act on the glycerol phosphate

102 cycle to promote protein glycosylation and mitochondrial dysfunction[40]; and
103 formamide (Fm) is shown to disrupt the cell's membrane, cytoskeleton and mitotic
104 spindle architecture[41; 42]. Furthermore, several CPAs have also been found to exhibit
105 genotoxicity effects; DMSO and formamide can denature DNA in calf thymus cells,
106 while EG and propylene glycol (PG) can induce chromosomal injuries in hamster
107 oocytes[41; 43]. Because of the different modes of toxicity, multiple CPAs at low-
108 concentration are often combined into a 'cocktail' solution in order to limit their
109 individual toxicities while at the same time obtaining an adequate total cryoprotective
110 solution concentration needed for tissue vitrification[27; 44; 45; 46; 47].

111 When describing toxicity effects of a multiple-CPA solution, an important
112 distinction is required; *direct* toxicity is the primary genotoxic or cytotoxic effects that a
113 CPA has on a cell, while *indirect* toxicity describes the effect of the molecular
114 interactions between CPAs within a solution which either enhance or reduce the
115 respective individual CPA toxicities. An example of this indirect toxicity effect is
116 demonstrated by the reduction in formamide's toxicity when DMSO is combined in the
117 same solution[48]. Determination of CPA toxicity interactions is difficult due to the
118 multiple combinations possible. The only comprehensive attempt on articular
119 chondrocytes has been performed by our group using porcine chondrocytes. We used five
120 different permeating CPAs in combinations up to 3M[21]. It was shown that toxicity
121 interactions did occur and could be described using regression analysis. The current study
122 was designed to evaluate the direct and indirect toxicity effects of five commonly used
123 permeating CPAs [dimethyl sulfoxide, ethylene glycol, propylene glycol, glycerol and
124 formamide] in human articular chondrocytes when placed into various combinations at

125 sufficient concentrations to vitrify[49]. We hypothesized that CPA direct and indirect
126 toxicities of high concentrations of permeating CPAs could be determined and quantified
127 in human articular chondrocytes.

128

129 **Methods & Materials**

130 ***Chondrocyte Isolation***

131 After ethical approval from the University of Alberta's ethical review board, a
132 total of 10 AC samples were obtained from donor patients undergoing elective total knee
133 replacements and transported in a sterile phosphate-buffered saline solution (PBS, pH
134 7.1, Invitrogen, Carlsbad, CA) and tested within 24hrs. Only areas scored as
135 Outerbridge[50] grade I or 0 were included. Cartilage samples were digested in 1mg/ml
136 solution of collagenase-DMEM-antibiotic solution (Sigma, Cat# C-9891, Lot#
137 084K8613, 357 units/mg solid, St. Louis, MO: Dulbecco's Modified Eagle Media,
138 DMEM F-12, Invitrogen, Carlsbad, CA: 1% Penicillin/Streptomycin, Invitrogen,
139 Carlsbad, CA). This was performed over a period of 6 hours in an incubator at 37°C and
140 5% CO₂. The digested solution was filtered through a 40µm cell strainer (Fisher
141 Scientific, Waltham, MA) and placed into a 50mL centrifuge tube and centrifuged for 6
142 minutes at 400x g and 20°C (Eppendorf 5810 R, Eppendorf, Hamburg, DE). The
143 supernatant was then removed and the pellet was re-centrifuged and re-suspended in both
144 sterile PBS and DMEM, eventually providing isolated chondrocytes without matrix. The
145 cell number was determined using a Coulter Counter Z2 (Beckman Coulter, Fullerton,
146 CA) and the chondrocytes were seeded onto a 96-well cell culture plate at a concentration
147 of 25,000 cells in 100µL suspension of solution (DMEM F-12, 1%

148 Penicillin/Streptomycin, 10% fetal bovine serum). The plates were then placed inside an
149 incubator for 48hrs (37°C, 5% CO₂) before they were exposed to the cryoprotective
150 solutions.

151

152 *Cryoprotective Solutions and Chondrocyte Exposure*

153 Five CPAs were used to create single-, three-, four- and five- combination
154 solutions (Table 1): dimethyl sulfoxide (DMSO), ethylene glycol (EG), propylene glycol
155 (PG), glycerol (Gy) and formamide (Fm). All twenty-one of the test solutions were
156 prepared as 6M and 9M stock solutions using the various CPAs in equal concentrations
157 and suspension media (DMEM F-12, 1% Penicillin/Streptomycin, and 10% fetal bovine
158 serum) and pre-cooled to 4C° to decrease biochemical reactions[22]. The 96 well plates
159 were removed from the incubator and placed on ice. Half of the volume of the wells were
160 removed with a pipette and replaced with the 6M test solution on top of the adhered cells,
161 thus creating a 3M solution environment in each well. After 5 minutes, 50 µL (half of the
162 volume of the well) was removed and replaced with an equal volume of the 9M test
163 solution, creating a final 6M environment. This stepwise increase in concentration was
164 employed to minimize the potential osmotic effects on the cells. For the 8.1M treatment,
165 an additional 70µL (70% of the volume) was removed and replaced with an equal volume
166 of the 9M test solution, thus creating an 8.1M environment in each well. Wells containing
167 only suspension media (DMEM/F12) and no CPAs were used as a positive control, and
168 wells containing 100% DMSO (known to be cytotoxic to chondrocytes)[22] was taken as
169 a negative control.

170 After 30 minutes of exposure, the CPAs were removed from the cells by the
171 following process: 25% of the test solution was removed with a pipette and replaced with
172 an equal volume of suspension media (DMEM/F12) and held for 5 minutes, creating an
173 environmental concentration of 6M in the wells that were initially subjected to 8.1M CPA
174 solutions. To further reduce the CPA concentration of all 6M solutions in a stepwise
175 manner, 50% of the test solution was removed and replaced with an equal volume of
176 suspension media. This was followed by two additional dilution steps removing 75% of
177 the remaining CPA solution each time, resulting in a final CPA concentration of
178 0.1875M. There were 10 donors in total. Six donors were used for the 1- and 3-CPA
179 combinations (32 wells – five 1-CPA solutions at both 6M and 8.1M, ten 3-CPA
180 combinations at both 6M and 8.1M, one negative control and one positive control) and
181 four donors were used for the 4- and 5-CPA combinations (14 wells – five 4-CPA
182 combinations at both 6M and 8.1M and one 5-CPA combination at both 6M and 8.1M,
183 one negative control and one positive control). Each donor provided one complete run of
184 either 1- and 3-CPA combinations (32 wells) or 4- and 5- combinations (14 wells).

185

186 *Evaluation of “direct” CPA toxicities via cell viability assays*

187 To assess the level of toxicity of each of the CPA solutions, a membrane integrity
188 assay was used to determine chondrocyte viability. A combination stain solution was
189 prepared using Syto13/ethidium bromide (0.86 μ M/8.6 μ M, Invitrogen, Carlsbad, CA /
190 Sigma-Aldrich, St. Louis, MO) in 1x PBS (Invitrogen, Carlsbad, CA). Syto13 is a cell
191 membrane permeable nucleic acid specific stain which emits a green fluorescence upon
192 excitation and ethidium bromide is a cell membrane non-permeable stain which is

193 specific for nucleic acids and emits a red fluorescence upon excitation. Therefore, cells
 194 with intact membranes block the ethidium bromide and emit a green fluorescence, while
 195 those with defective membranes allow the penetration of ethidium bromide and emit a
 196 red fluorescence. The wells of the 96-well plate were drained by inversion and 40µl of
 197 the combination stain solution was added to each of the wells (thus further reducing the
 198 CPA concentration in the wells to almost nil). The cells and stain were left to incubate
 199 for 30 minutes at room temperature (~21°C) in a dark environment. Chondrocyte
 200 membrane integrity was determined by fluorescent microscopy (Nikon Eclipse TE 2000-
 201 U fluorescent microscope, NIS Elements software [v. F 2.30, Nikon, Tokyo, JP]) and
 202 cell counts (live/dead) were made using a visual software program (Viability 3.2.0.0,
 203 Cryolab, University of Alberta)[51]. The chondrocyte survival rates were normalized and
 204 are reported as the number of intact (green-fluorescing) cells post-treatment divided by
 205 the number of intact cells in the self-control. This calculation was chosen as a
 206 conservative measure of cell survival that accounts for differences among samples in
 207 initial cell health and cell attachment properties.

208

209 ***Evaluation of “indirect” toxicities via Statistical Analysis***

210 The following mathematical model was used for cell recovery, y.

$$\begin{aligned}
 y = & \alpha + \sum_{i=1}^5 \beta_i x_i + \sum_{i=1}^5 \sum_{j=i+1}^5 \gamma_{ij} x_i x_j + \sum_{i=1}^5 \sum_{j=i+1}^5 \sum_{k=j+1}^5 \emptyset_{ijk} x_i x_j x_k \\
 & + \sum_{i=1}^5 \sum_{j=i+1}^5 \sum_{k=j+1}^5 \sum_{l=k+1}^5 \delta_{ijkl} x_i x_j x_k x_l
 \end{aligned}
 \tag{1}$$

211

212 where x_i is the molar concentration of the i^{th} cryoprotective agent, α represents the
 213 expected control survival, and the symbols β , γ , \emptyset , and δ are the various regression

214 coefficients describing the strength of various direct and indirect toxicities of CPAs. The
215 β_i coefficients, assume a linear dose-toxicity relationship for each CPA and describe the
216 direct toxicity strength of each cryoprotectant i —that is, β_i indicates the amount that the
217 cell recovery is reduced per molar increase in that CPA's concentration. The β_i
218 coefficients are expected to have negative values as the presence of a single CPA
219 generally reduces cell survival. The last three terms in Equation 1 represent higher order
220 corrections to the control cell survival and direct toxicities, and are called “indirect
221 toxicities”. The coefficients γ , \emptyset , and δ represent the strength of the indirect toxicities or
222 the additional contribution to cell recovery of a particular combination of CPAs above
223 that which would be expected by considering the effect of each CPA individually. The
224 last three terms in equation 1 involving these coefficients account for changes in solution
225 toxicity due to interactions between CPAs in solution. The coefficients γ , \emptyset , and δ can be
226 expected to be either negative or positive. Those combinations for which CPA–CPA
227 interactions caused an increased level of solution toxicity have negative coefficients,
228 while those combinations for which CPA–CPA interactions lead to a reduced level of
229 toxicity have positive coefficients.

230

231 Using the data from the cell viability assays, the coefficients were identified using linear
232 least squares multiple regression. Various models were tested, including models without
233 indirect effects (i.e., neglecting the last three terms on the right hand side of equation 1),
234 and models that only included terms up to 2nd order and 3rd order, respectively. However,
235 the model that included all the terms including 4th order terms in equation 1 best
236 described the experimental data. After the regression was completed, hypotheses tests

237 were conducted to ensure that the estimated value of each coefficient was significant. The
238 null hypothesis was that the coefficient was indistinguishable from zero at the 95%
239 confidence level, and the tests were conducted using the standard deviation of each
240 coefficient obtained from the regression. The tests established that each coefficient was
241 significant and different from zero. The statistical analysis was performed using Matlab
242 R2009b software (The MathWorks, Inc., Natick, MA).

243

244 **Results**

245 *Single and combination CPA toxicities*

246 The positive controls showed a cell survival rate of 54.9 ± 2.7 (n=10) and the
247 negative controls had cell survival rates of 0% (Figure 1). Overall, the single-CPA
248 solutions were more toxic than the multiple-CPA solutions (Table 2). This finding was
249 consistent in both the 6.0M and 8.1M concentrations. Furthermore, between the two
250 concentrations, the 8.1M solutions resulted in significantly greater chondrocyte loss
251 compared to the 6.0M solutions ($P < 0.05$). Among the *single*-CPA solutions, formamide
252 was the most toxic agent and DMSO was the least toxic. However, when used in
253 *multiple*-CPA solutions, propylene glycol was found to be the most toxic CPA. In
254 general, all solutions that contained PG resulted in a similar range of chondrocyte
255 survival of between 0.05-5.09% (6.0M = 0.18 – 5.09%; 8.1M = 0.05 – 2.85%). However,
256 CPA combination solutions where PG was excluded yielded significantly greater cell
257 membrane integrity rates ($P < 0.001$, Table 2). In fact, the average cell survival rates of the
258 PG-excluded combination solutions ranged from 7.93-39.78% for the 6.0M solutions and
259 1.05-7.20% for the 8.1M solutions. The greatest chondrocyte survival rates

260 (approximately 40%) were obtained with the DMSO-EG-Gy-Fm combination solution,
261 followed by the Gy-EG-Fm and Gy-DMSO-Fm solutions (Table 2).

262

263 ***Combination CPA “Indirect” Toxicity Effects***

264 The interactions between the CPAs had measurable effects on a solution’s
265 toxicity; various CPA interactions resulted in either additive or subtractive effects on the
266 final solution toxicity (Table 3). Two-CPA interactions increased the final toxicity of the
267 solution above that expected from the single-CPA direct toxicities as evidenced by the
268 negative values of the γ_{ij} coefficients. Three-CPA interactions decreased the final toxicity
269 of the solution below that expected from the single-CPA direct toxicities and two-CPA
270 indirect toxicities as evidenced by the positive values of the \emptyset_{ijk} coefficients. Four-CPA
271 interactions increased the final toxicity of the solution CPA above that expected from the
272 single-CPA direct toxicities and two- and three-CPA indirect toxicities as evidenced by
273 the negative values of the δ_{ijkl} coefficients. While some interactions resulted in
274 antagonistic toxicity effects which reduced the CPA solution’s final toxicity (eg. the 3-
275 combination CPA solutions), other combinations resulted in synergistic toxicity effects
276 which further increased the solution’s toxicity (eg. the 2- and 4-combination CPA
277 solutions). Of note, the values of the coefficients are not as significant as their ordinality
278 in terms of grading the indirect toxicities of the different combinations in relation to one
279 another.

280

281 **Discussion**

282 The ideal CPA solution for cartilage vitrification depends on determining the least
283 toxic CPA solution as well as optimizing its tissue-permeability and efficacy in
284 vitrification. However, in order to achieve this, a clear understanding of the direct and
285 indirect toxicities is necessary to develop a safe and minimally toxic CPA solution. This
286 study has attempted to investigate both the direct toxicity effects of CPAs in various CPA
287 combinations, as well as the indirect toxicity effects of combination CPAs. The obtained
288 coefficients provide us with an understanding of the CPA toxicities so that we can
289 mathematically predict which combinations of CPAs will produce the lowest degree of
290 toxicity without having to empirically test all possible combinations.

291 Surprisingly, the chondrocyte survival rates for the positive controls were
292 approximately 60%. This suggests that environmental factors such as pre-existing
293 condition of the cartilage, harvesting method and tissue processing were important in
294 determining chondrocyte survival. Another important factor was chondrocyte exposure to
295 the CPA solutions. Previous studies have shown that even though CPAs all share the
296 similar function of preventing cryopreservation-induced injuries, their degree and
297 mechanism of toxicity varies among species[24; 52; 53]. However, when we compare
298 this data to our previous study which employed porcine chondrocytes, there are several
299 important similarities: multiple-CPA solutions are less toxic than single-CPA solutions of
300 the same concentration; higher concentration CPA solutions are more toxic; and PG is
301 one of the most toxic CPAs[21].

302 An important concept presented within this study is that of direct and indirect
303 toxicity effects. It has been shown that combining CPAs can result in lower toxicity when
304 compared to a single CPA at the same total concentration[54; 55]. It has not been

305 determined whether the overall lower toxicity is due to the actual reduction of the
306 concentration of each individual CPA or interactions between the CPAs or a combination
307 of both of these mechanisms. As noted here, multiple-CPA solution toxicities are
308 *nonlinear* and the final CPA solution's toxicity is not equal to the sum of its individual
309 CPA toxicities. This nonlinear pattern of toxicity is best explained by the indirect toxicity
310 concept arising from molecular interactions between CPAs and their biochemical targets
311 and between the CPAs themselves. These interactions alter the activities and toxicities of
312 the CPAs within a combination and produce either synergistic (i.e. enhanced) or
313 antagonistic (i.e. reduced) effects on the final CPA solution's toxicity. The exact
314 mechanism of this property is unknown, but we propose some plausible mechanisms. For
315 example, PG may polarize another CPA's molecular charges and render that CPA more
316 toxic or potent. Considering PG's toxicity to the cell's cytoskeleton, it may interfere with
317 the mobilization of organelles and compounds necessary for repair and adaptation. Other
318 possibilities include a CPA compounding the mitochondrial dysfunction induced by
319 glycerol by inhibiting alternative energy sources for the cell, or the CPA may prevent the
320 mobilization of new membrane proteins needed for survival when a cell's membrane ion
321 channels are injured by DMSO. Regardless of the mechanism, the presence of indirect
322 toxicities due to CPA interactions within a combination does play a quantifiable role
323 which has been elucidated in this research.

324 Previous methods of describing and predicting CPA toxicities have focused on
325 quantifying the direct toxicities of CPAs based on their functional polar groups and
326 vitrification concentrations[56]. While the coefficients determined in the current study
327 are only meant to represent the indirect toxicity effects of a combination, their actual

328 values are not as significant as their ordinality in terms of grading a combination
329 solution's indirect toxicity in relation to other combinations. Interestingly, all the 3-CPA
330 combinations demonstrated positive coefficient values (i.e. interactions that reduce
331 toxicity), while the 2- and 4-CPA combinations had negative coefficients (i.e. interactions
332 which increased the solutions toxicity). One possible explanation is that the 3-CPA
333 combination solutions may represent a cross-over point between toxicity due to CPA-
334 CPA interactions (more likely to occur in the 2-CPA combinations due to the higher
335 concentrations of the 2 CPAs involved) and the toxicity due to increased mechanisms of
336 direct cellular injury (due to the greater overlap and number of cellular targets and
337 toxicity mechanisms with 4-CPA combinations). A second explanation involves the
338 toxicity relationships of the CPA's, which may be linear or non-linear (eg. curvi-linear or
339 sigmoidal). In fact, even though a CPA's toxicity-dose relationship may be linear in
340 isolation, when combined with other CPAs the relationship may become non-linear.
341 Therefore, because our indirect toxicity model assumes a linear dose-toxicity
342 relationship, by applying a linear least squares regression analysis to a 'curved' dose-
343 toxicity relationship we may be over- or under-estimating the contributions of the CPA's
344 indirect toxicity effects. That stated, other models were tested including models without
345 indirect effects and models that included terms up the 2nd order and 3rd order. However,
346 the model that included all terms including 4th order terms in equation 1 best described
347 the experimental data. Nevertheless, until further studies become available which better
348 characterize the CPA-cell toxicity relationship, the current model can provide a
349 preliminary framework to describe the indirect toxicity effects based on the 1-, 3-, 4- and

350 5-CPA data obtained, and provide us with an effective method for predicting which CPA
351 interactions will optimize chondrocyte survival rates.

352 The incorporation of the coefficients into a CPA's toxicity profile provides a more
353 accurate framework for predicting and describing the toxicity characteristics of CPAs, so
354 that as the data is expanded to include variations in concentrations and further
355 combinations, the model will become more accurate. Nevertheless, considering that the
356 regressions from the data are based on a 'best-fit' model, conclusions regarding physical
357 or biochemical properties and reactions cannot be reliably inferred without first testing
358 the accuracy of the model.

359 With regards to the single-CPA solution data, we found that formamide was the
360 most toxic of the single CPA solutions and this finding is similarly reported in other
361 studies[57; 58]. However, when analyzing the direct and indirect multiple-CPA toxicity
362 data, we find that PG was the most toxic CPA. In fact, propylene glycol has been found
363 to be a significantly toxic CPA across a variety of species[26; 44; 59] , and when placed
364 in the context of our data, we find that combinations which excluded propylene glycol
365 had significantly better chondrocyte survival rates ($P<0.01$). The mechanisms by which
366 PG exhibits its toxicity is still not completely established; however a few studies have
367 already demonstrated its harmful effects on cell membrane permeability, mitochondrial
368 activity, thymidine incorporation into DNA and lysosomal activation[42; 60; 61].
369 Furthermore, when analyzing PG within the context of the indirect toxicities, we find that
370 all of the two-combination CPA solutions which included PG had the most negative
371 coefficients, suggesting that when compared to the other CPAs tested, PG significantly
372 enhances the toxicity of a combination solution. Therefore, its inclusion within a

373 multiple-CPA solution for isolated chondrocytes should be avoided. Nevertheless, the
374 reason for which formamide is found to be the most toxic CPA when in isolation and PG
375 the most toxic in combination is likely related to the indirect toxicity concept where PG
376 may not be the most toxic CPA, but its toxic properties enhance the toxic effects of
377 surrounding CPAs. For this reason, PG is a harmful CPA to isolated chondrocytes when
378 used in a multiple-CPA solution.

379 Overall, similar to other reports, we determined that multiple-CPA solutions are
380 less toxic than the single CPA solutions[21; 47; 48] , and therefore a larger range of
381 combinations of CPA solutions should be tested. Of course, many other factors may also
382 be adjusted which include variations in individual CPA concentrations within the
383 solution, the role of the order of CPA addition, the temperature of introduction, and the
384 exposure time. Furthermore, considering the more toxic nature of permeable CPAs, there
385 may be benefit to employing a balanced combination of non-permeable and permeable
386 CPAs[23; 59; 61]. Importantly, toxicity effects may be altered by removing the cells from
387 their native tissue and results may differ with cells *in situ*[54]. This study used
388 chondrocytes isolated from the matrix to avoid permeation issues but cells *in situ* may
389 react differently than cells in solution. Thus, it is important to relate these results
390 specifically to isolated chondrocytes as opposed to those still in the matrix. It is possible
391 that 5 minutes exposure is insufficient time. We believe this is unlikely due to the
392 published permeation rates of DMSO, PG and glycerol into chondrocytes[62; 63] but it
393 should be noted that these rates were at 20°C. Only the permeation rate of EG into
394 chondrocytes has not been recorded. In many of the combinations, there was very little
395 cell recovery. Even more informative data may be achieved by using lower

396 concentrations (we used these high concentrations in order to relate the results to
397 vitrification) or to expose the cells for a shorter period of time. Nevertheless, the results
398 of this study have helped emphasize the possibility of reducing a CPA solution's toxicity
399 by using a selective combination of CPAs with good toxicity interactions.

400

401 **Conclusions**

402 Multiple-CPA solutions are less cytotoxic than single-CPA solutions of the same
403 total concentration. CPAs exhibit direct and indirect toxicities, where specific molecular
404 interactions can either enhance or reduce the toxicities of other CPAs within a
405 combination solution. For chondrocytes from human AC, formamide was the most toxic
406 CPA when only single-CPA solutions were used. Propylene glycol was the most toxic of
407 the permeating CPAs tested when included in multiple-CPA solutions and its inclusion
408 within a combination resulted in significantly higher indirect toxicities. Of the
409 combination solutions tested, the 6.0M DMSO-ethylene glycol-formamide-glycerol
410 combination solution resulted in the highest human AC chondrocyte survival of
411 approximately 40%.

412

413 **Acknowledgements**

414 This research was funded by the Canadian Institutes of Health Research (MOP 93805).
415 JAWE holds a Canada Research Chair in Thermodynamics.

416 Figure Legend

417 **Figure 1:** Digitized images of plates containing, A: Positive control; B: Negative control;
418 and C: DMSO-EG-Gy-Fm solution that demonstrated the highest cell recovery of all
419 solutions tested. Fluorescent staining by Syto13 (green = intact membranes) and ethidium
420 bromide (red = disrupted membranes). Images were taken at 4x magnification. Scale bars
421 represent 100 μm .

422

423 **Table 1. CPA solutions*:**

Single-CPA solutions

1. DMSO 2. EG 3. PG 4. Gy 5. Fm

Three-CPA Combination solutions

6. EG-DMSO-PG 7. EG-DMSO-Gy 8. EG-DMSO-Fm 9. EG-PG-Gy
10. EG-PG-Fm 11. EG-Gy-Fm 12. Gy-DMSO-PG 13. Gy-DMSO-Fm
14. Gy-PG-Fm 15. DMSO-PG-Fm

Four-CPA Combination solutions

16. DMSO-PG-EG-Gy 17. DMSO-PG-EG-Fm 18. DMSO-PG-Gy-Fm
19. DMSO-EG-Gy-Fm 20. PG-EG-Gy-Fm

Five-CPA Combination solutions

21. DMSO-PG-EG-Gy-Fm

424 *DMSO (dimethyl sulfoxide), EG (ethylene glycol), PG (propylene glycol),

425 Gy (glycerol), Fm (formamide)

426

427

Table 2: CPA solutions and chondrocyte survival rates

Solution	6.0M		8.1M	
	% Survival	SE	% Survival	SE
D-D-D	3.00	0.01	0.97	0.00
P-P-P	0.10	0.00	0.03	0.00
E-E-E	0.34	0.00	0.09	0.00
G-G-G	0.19	0.00	0.06	0.00
F-F-F	0.02	0.00	0.01	0.00
G-E-D	7.93	0.04	4.32	0.01
G-D-F	24.03	0.05	5.07	0.04
G-E-F	28.43	0.03	2.86	0.04
G-E-P	0.20	0.00	0.05	0.00
G-P-F	0.18	0.00	0.09	0.00
E-D-F	9.09	0.01	1.05	0.01
G-D-P	0.45	0.00	0.17	0.00
E-P-F	0.20	0.01	0.70	0.00
E-D-P	0.23	0.00	0.08	0.00
D-P-F	0.25	0.00	0.07	0.00
D-P-E-G	0.41	0.00	0.20	0.00
D-P-E-F	0.48	0.00	0.24	0.00
D-P-G-F	5.09	0.03	2.85	0.00
D-E-G-F	39.78	0.07	7.20	0.09
P-E-G-F	0.60	0.00	0.35	0.00
D-P-E-G-F	3.25	0.01	1.45	0.01
100% DMSO	0.03	0.00	0.02	0.00

428

429

430 *D = dimethyl sulfoxide, P = propylene glycol, E = ethylene glycol, G = glycerol, F =

431 formamide

432

Table 3: Coefficient toxicities of CPAs

<u>Coefficient</u>	<u>Agent / Combination^{±,¶}</u>	<u>Value</u>	<u>Std. Deviation</u>	<u>Notes</u>
α	Control*	48.27	.06072	<i>Positive control containing suspension media only.</i>
β	D	-6.58	.02582	<i>Single-CPA solution's direct toxicity effects</i>
	P	-6.97	.02580	
	E	-6.80	.02581	
	G	-6.83	.02581	
	F	-6.81	.02580	
γ_{ij}	D + P	-0.8809	0.02301	<i>Multiple-CPA solution's indirect toxicity effects; the coefficient represents the toxicity effects due to the respective CPA interactions within a corresponding combination</i>
	D + E	-0.6754	0.02300	
	D + G	-0.2992	0.02303	
	D + F	-0.6231	0.02303	
	P + E	-1.0707	0.02319	
	P + G	-1.0333	0.02319	
	P + F	-0.9299	0.02322	
	E + G	-0.8731	0.02332	
	E + F	-0.6976	0.02307	
\emptyset_{ijk}	D + P + E	1.0787	0.02074	
	D + P + G	0.9308	0.02074	
	D + P + F	0.1022	0.02074	
	D + E + G	0.9966	0.02073	
	D + E + F	1.1393	0.02074	
	D + G + F	1.7797	0.02074	
	P + E + G	1.2734	0.02074	
	P + E + F	1.1535	0.02074	
	P + G + F	0.9322	0.02074	
	E + G + F	2.3360	0.02074	
	δ_{ijkl}	D + P + E + G	-0.5773	0.0167
D + P + E + F		-0.6301	0.0168	
D + P + G + F		-0.1047	0.0168	
D + E + G + F		-0.1185	0.0169	
P + E + G + F		-0.1358	0.0180	

434 [±] Positive coefficients represent interactions which reduced the final solution's toxicity,
 435 while those with negative coefficients represent interactions which increased the final
 436 solutions toxicity.

437 [¶]D = dimethyl sulfoxide, E = ethylene glycol, P = propylene glycol, G = glycerol, and F =
 438 formamide

439 * DMEM F-12, 1% Penicillin/Streptomycin, and 10% fetal bovine serum

440

441 **References**

- 442 [1] Arthritis, Public Health Agency of Canada, 2010.
443 [2] C. Health, Health Canada; Economic Impact of Illness in Canada 1998. Ottawa:
444 Public Works and Government Services Canada Catalogue # H21-136/1998E,
445 (2002).
446 [3] A.F. Praemer, and S. Rice, Musculoskeletal conditions in the United States, American
447 Academy of Orthopaedic Surgeons, Rosemont, IL, 1999.
448 [4] D.W. Jackson, and T.M. Simon, Chondrocyte transplantation [see comments].
449 *Arthroscopy* 12, (1996) 732-738.
450 [5] S.T. Ball, D. Amiel, S.K. Williams, W. Tontz, A.C. Chen, R.L. Sah, and W.D.
451 Bugbee, The effects of storage on fresh human osteochondral allografts. *Clin*
452 *Orthop Relat Res*, (2004) 246-52.
453 [6] R.J. Williams, 3rd, J.C. Dreese, and C.T. Chen, Chondrocyte survival and material
454 properties of hypothermally stored cartilage: an evaluation of tissue used for
455 osteochondral allograft transplantation. *Am J Sports Med* 32, (2004) 132-9.
456 [7] K.G. Brockbank, Effects of cryopreservation upon vein function in vivo. *Cryobiology*
457 31, (1994) 71-81.
458 [8] M.L. Check, D.J. Check, J.H. Check, R. Long, and M. Press, Effect of shortened
459 exposure time to the critical period for ice crystal formation on subsequent post-
460 thaw semen parameters from cryopreserved sperm. *Arch Androl* 32, (1994) 63-
461 67.
462 [9] L.E. McGann, A.R. Turner, M.J. Allalunis, and J.M. Turc, Cryopreservation of
463 human peripheral blood stem cells: optimal cooling and warming conditions.
464 *Cryobiology* 18, (1981) 469-472.
465 [10] N.M. Jomha, G. Lavoie, K. Muldrew, N.S. Schachar, and L.E. McGann,
466 Cryopreservation of intact human articular cartilage. *J Orthop Res* 20, (2002)
467 1253-5.
468 [11] T. Malinin, H.T. Temple, and B.E. Buck, Transplantation of osteochondral allografts
469 after cold storage. *J Bone Joint Surg Am* 88, (2006) 762-70.
470 [12] C. Ohlendorf, W.W. Tomford, and H.J. Mankin, Chondrocyte survival in
471 cryopreserved osteochondral articular cartilage. *J Orthop Res* 14, (1996) 413-416.
472 [13] G.M. Fahy, T.H. Lilley, H. Linsdell, M.S. Douglas, and H.T. Meryman,
473 Cryoprotectant toxicity and cryoprotectant toxicity reduction: in search of
474 molecular mechanisms. *Cryobiology* 27, (1990) 247-68.
475 [14] B. Han, and J.C. Bischof, Direct cell injury associated with eutectic crystallization
476 during freezing. *Cryobiology* 48, (2004) 8-21.
477 [15] D.E. Pegg, Principles of cryopreservation. *Methods Mol Biol* 368, (2007) 39-57.
478 [16] E.M. Kolibianakis, C.A. Venetis, and B.C. Tarlatzis, Cryopreservation of human
479 embryos by vitrification or slow freezing: which one is better? *Curr Opin Obstet*
480 *Gynecol* 21, (2009) 270-4.
481 [17] K.E. Loutradi, E.M. Kolibianakis, C.A. Venetis, E.G. Papanikolaou, G. Pados, I.
482 Bontis, and B.C. Tarlatzis, Cryopreservation of human embryos by vitrification or
483 slow freezing: a systematic review and meta-analysis. *Fertil Steril* 90, (2008) 186-
484 93.

- 485 [18] K.G. Brockbank, Z.Z. Chen, and Y.C. Song, Vitrification of porcine articular
486 cartilage. *Cryobiology* 60, (2010) 217-21.
- 487 [19] G.M. Fahy, D.I. Levy, and S.E. Ali, Some emerging principles underlying the
488 physical properties, biological actions, and utility of vitrification solutions.
489 *Cryobiology* 24, (1987) 196-213.
- 490 [20] G.M. Fahy, B. Wowk, J. Wu, J. Phan, C. Rasch, A. Chang, and E. Zendejas,
491 Cryopreservation of organs by vitrification: perspectives and recent advances.
492 *Cryobiology* 48, (2004) 157-78.
- 493 [21] N.M. Jomha, A.D. Weiss, J. Fraser Forbes, G.K. Law, J.A. Elliott, and L.E.
494 McGann, Cryoprotectant agent toxicity in porcine articular chondrocytes.
495 *Cryobiology* 61, (2010) 297-302.
- 496 [22] H.Y. Elmoazzen, A. Poovadan, G.K. Law, J.A. Elliott, L.E. McGann, and N.M.
497 Jomha, Dimethyl sulfoxide toxicity kinetics in intact articular cartilage. *Cell*
498 *Tissue Bank* 8, (2007) 125-33.
- 499 [23] R.H. Hammerstedt, J.K. Graham, and J.P. Nolan, Cryopreservation of mammalian
500 sperm: what we ask them to survive. *J Androl* 11, (1990) 73-88.
- 501 [24] J.M. Blanco, G. Gee, D.E. Wildt, and A.M. Donoghue, Species variation in osmotic,
502 cryoprotectant, and cooling rate tolerance in poultry, eagle, and peregrine falcon
503 spermatozoa. *Biol Reprod* 63, (2000) 1164-71.
- 504 [25] J.M. Blanco, J.A. Long, G. Gee, A.M. Donoghue, and D.E. Wildt, Osmotic tolerance
505 of avian spermatozoa: influence of time, temperature, cryoprotectant and
506 membrane ion pump function on sperm viability. *Cryobiology* 56, (2008) 8-14.
- 507 [26] J.M. Blanco, J.A. Long, G. Gee, D.E. Wildt, and A.M. Donoghue, Comparative
508 cryopreservation of avian spermatozoa: benefits of non-permeating
509 osmoprotectants and ATP on turkey and crane sperm cryosurvival. *Anim Reprod*
510 *Sci* 123, (2011) 242-8.
- 511 [27] R. Fabbri, Cryopreservation of human oocytes and ovarian tissue. *Cell Tissue Bank*
512 7, (2006) 113-22.
- 513 [28] S.R. Lyu, W.T. Wu, C.C. Hou, and W.H. Hsieh, Study of cryopreservation of
514 articular chondrocytes using the Taguchi method. *Cryobiology* 60, (2010) 165-76.
- 515 [29] R. McClean, W.V. Holt, Y.P. Zee, A. Lisle, and S.D. Johnston, The effect of
516 cryoprotectant on kangaroo sperm ultrastructure and mitochondrial function.
517 *Cryobiology* 57, (2008) 297-303.
- 518 [30] Y. Yamaji, D.M. Valdez, Jr., S. Seki, K. Yazawa, C. Urakawa, B. Jin, M. Kasai,
519 F.W. Kleinhans, and K. Edashige, Cryoprotectant permeability of aquaporin-3
520 expressed in *Xenopus* oocytes. *Cryobiology* 53, (2006) 258-67.
- 521 [31] H.Y. Elmoazzen, J.A. Elliott, and L.E. McGann, The effect of temperature on
522 membrane hydraulic conductivity. *Cryobiology* 45, (2002) 68-79.
- 523 [32] M. Kasai, and T. Mukaida, Cryopreservation of animal and human embryos by
524 vitrification. *Reprod Biomed Online* 9, (2004) 164-70.
- 525 [33] S.W. Jacob, and J.C. de la Torre, Pharmacology of dimethyl sulfoxide in cardiac and
526 CNS damage. *Pharmacol Rep* 61, (2009) 225-35.
- 527 [34] B. Bakar, E.A. Kose, S. Sonal, A. Alhan, K. Kilinc, and I.S. Keskil, Evaluation of
528 the neurotoxicity of DMSO infused into the carotid artery of rat. *Injury*, (2011).
- 529 [35] J. Vondracek, K. Soucek, M.A. Sheard, K. Chramostova, Z. Andrysik, J.
530 Hofmanova, and A. Kozubik, Dimethyl sulfoxide potentiates death receptor-

531 mediated apoptosis in the human myeloid leukemia U937 cell line through
532 enhancement of mitochondrial membrane depolarization. *Leuk Res* 30, (2006) 81-
533 9.

534 [36] T. Zampolla, E. Spikings, T. Zhang, and D.M. Rawson, Effect of methanol and
535 Me2SO exposure on mitochondrial activity and distribution in stage III ovarian
536 follicles of zebrafish (*Danio rerio*). *Cryobiology* 59, (2009) 188-94.

537 [37] R.K. Koiri, and S.K. Trigun, Dimethyl sulfoxide activates tumor necrosis
538 factor- α -p53 mediated apoptosis and down regulates D-fructose-6-phosphate-
539 2-kinase and lactate dehydrogenase-5 in Dalton's lymphoma in vivo. *Leuk Res* 35,
540 (2011) 950-6.

541 [38] S. Sharma, E. Raymond, H. Soda, E. Izbicka, K. Davidson, R. Lawrence, and D.D.
542 Von Hoff, Dimethyl sulfoxide (DMSO) causes a reversible inhibition of
543 telomerase activity in a Burkitt lymphoma cell line. *Leuk Res* 22, (1998) 663-70.

544 [39] D. Jammalamadaka, and S. Raissi, Ethylene glycol, methanol and isopropyl alcohol
545 intoxication. *Am J Med Sci* 339, (2010) 276-81.

546 [40] A.R. Hipkiss, Proteotoxicity and the contrasting effects of oxaloacetate and glycerol
547 on *Caenorhabditis elegans* life span: a role for methylglyoxal? *Rejuvenation Res*
548 13, (2010) 547-51.

549 [41] M. Aye, C. Di Giorgio, M. De Mo, A. Botta, J. Perrin, and B. Courbiere, Assessment
550 of the genotoxicity of three cryoprotectants used for human oocyte vitrification:
551 dimethyl sulfoxide, ethylene glycol and propylene glycol. *Food Chem Toxicol* 48,
552 (2010) 1905-12.

553 [42] K.M. Morshed, S.K. Jain, and K.E. McMartin, Propylene glycol-mediated cell injury
554 in a primary culture of human proximal tubule cells. *Toxicol Sci* 46, (1998) 410-
555 7.

556 [43] G. Bonner, and A.M. Klibanov, Structural stability of DNA in nonaqueous solvents.
557 *Biotechnol Bioeng* 68, (2000) 339-44.

558 [44] J. Ali, and J.N. Shelton, Design of vitrification solutions for the cryopreservation of
559 embryos. *J Reprod Fertil* 99, (1993) 471-7.

560 [45] A.M. Dalimata, and J.K. Graham, Cryopreservation of rabbit spermatozoa using
561 acetamide in combination with trehalose and methyl cellulose. *Theriogenology*
562 48, (1997) 831-41.

563 [46] F. Lahnsteiner, The effect of internal and external cryoprotectants on zebrafish
564 (*Danio rerio*) embryos. *Theriogenology* 69, (2008) 384-96.

565 [47] A. Lawson, H. Ahmad, and A. Sambanis, Cytotoxicity effects of cryoprotectants as
566 single-component and cocktail vitrification solutions. *Cryobiology* 62, (2011)
567 115-22.


568 [48] G.M. Fahy, Cryoprotectant toxicity neutralization. *Cryobiology* 60, (2010) S45-53.

569 [49] A.D. Weiss, J.F. Forbes, A. Scheuerman, G.K. Law, J.A. Elliott, L.E. McGann, and
570 N.M. Jomha, Statistical prediction of the vitrifiability and glass stability of multi-
571 component cryoprotective agent solutions. *Cryobiology* 61, (2010) 123-7.

572 [50] E.C. Rodriguez-Merchan, and P. Gomez-Cardero, The outerbridge classification
573 predicts the need for patellar resurfacing in TKA. *Clin Orthop Relat Res* 468,
574 (2010) 1254-7.

- 575 [51] N.M. Jomha, P.C. Anoop, J.A.W. Elliott, K. Bagnall, and L.E. McGann, Validation
576 and reproducibility of computerised cell-viability analysis of tissue slices. *BMC*
577 *Musculoskelet Disord* 4, (2003) 5.
- 578 [52] J.P. Barbas, and R.D. Mascarenhas, Cryopreservation of domestic animal sperm
579 cells. *Cell Tissue Bank* 10, (2009) 49-62.
- 580 [53] H. Yang, M. Norris, R. Winn, and T.R. Tiersch, Evaluation of cryoprotectant and
581 cooling rate for sperm cryopreservation in the euryhaline fish medaka *Oryzias*
582 *latipes*. *Cryobiology* 61, (2010) 211-9.
- 583 [54] L.H. Campbell, and K.G.M. Brockbank, Cryopreservation of porcine aortic heart
584 valve leaflet-derived myofibroblasts. *Biopreservation and Biobanking* 8, (2010)
585 211-217.
- 586 [55] G.M. Fahy, Cryoprotectant toxicity neutralization. *Cryobiology*, (2009).
- 587 [56] G.M. Fahy, B. Wowk, J. Wu, and S. Paynter, Improved vitrification solutions based
588 on the predictability of vitrification solution toxicity. *Cryobiology* 48, (2004) 22-
589 35.
- 590 [57] T.H. Dresser, E.R. Rivera, F.J. Hoffmann, and R.A. Finch, Teratogenic assessment
591 of four solvents using the Frog Embryo Teratogenesis Assay--Xenopus (FETAX).
592 *J Appl Toxicol* 12, (1992) 49-56.
- 593 [58] V. Vuthiphandchai, S. Chomphuthawach, and S. Nimrat, Cryopreservation of red
594 snapper (*Lutjanus argentimaculatus*) sperm: effect of cryoprotectants and cooling
595 rates on sperm motility, sperm viability, and fertilization capacity.
596 *Theriogenology* 72, (2009) 129-38.
- 597 [59] I.A. Nascimento, M.B. Leite, M.M. Sampaio de Araujo, G. Sansone, S.A. Pereira,
598 and E.M. do Espirito Santo, Selection of cryoprotectants based on their toxic
599 effects on oyster gametes and embryos. *Cryobiology* 51, (2005) 113-7.
- 600 [60] M. Hagedorn, E. Hsu, F.W. Kleinans, and D.E. Wildt, New approaches for
601 studying the permeability of fish embryos: toward successful cryopreservation.
602 *Cryobiology* 34, (1997) 335-47.
- 603 [61] M. Hagedorn, F.W. Kleinans, D.E. Wildt, and W.F. Rall, Chill sensitivity and
604 cryoprotectant permeability of dechorionated zebrafish embryos, *Brachydanio*
605 *rerio*. *Cryobiology* 34, (1997) 251-63.
- 606 [62] X. Xu, Z. Cui, and J.P. Urban, Measurement of the chondrocyte membrane
607 permeability to Me₂SO, glycerol and 1,2-propanediol. *Med Eng Phys* 25, (2003)
608 573-9.
- 609 [63] L.E. McGann, M. Stevenson, K. Muldrew, and N. Schachar, Kinetics of osmotic
610 water movement in chondrocytes isolated from articular cartilage and applications
611 to cryopreservation. *J Orthop Res* 6, (1988) 109-115.
- 612
- 613

Figure 1



*Statement of Funding

This research was funded by the Canadian Institutes of Health Research which did not have any role in the design and performance of this study.

Conflict of Interest

The authors have no conflicts of interest.